The deal, which is worth as much as US$495 million and grants Pfizer exclusive rights to market the drug on the Chinese mainland, includes upfront payment as well as milestone-based fees, Sciwind said, without disclosing the specifics.
(Feb 24): Pfizer Inc has acquired exclusive rights to commercialise an obesity therapy in China, strengthening its push into the fast-growing weight loss market.
The American drugmaker struck a deal with local startup Hangzhou Sciwind Bioscience Co for ecnoglutide, a drug recently approved in China for diabetes and currently under regulatory review for obesity, according to a statement on WeChat.
